Department of Genetics, University of Cambridge

Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.

Retrieved on: 
Thursday, July 28, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors.
  • Throughout my career, I have been drawn to unique targets such as microglia that have the potential to transform treatments for rare and underserved diseases.
  • Vigils patient-centered approach to developing microglia-targeted therapeutics aligns with this vision as well as my background, Dr. Bruhn said.
  • Dr. Bruhn currently serves on the Board of Directors of Pliant Therapeutics and Travere Therapeutics.

NonExomics Unveils Technology to Decode Dark Genome for Diagnosis and Treatment of Diseases Like Cancer

Retrieved on: 
Monday, June 20, 2022

Beverly, Massachusetts--(Newsfile Corp. - June 20, 2022) - NonExomics has announced the launch of new technology to explore the dark genome for rapid diagnosis and treatment of many common diseases like cancer, bipolar disorder, cardiovascular diseases, and schizophrenia.

Key Points: 
  • Beverly, Massachusetts--(Newsfile Corp. - June 20, 2022) - NonExomics has announced the launch of new technology to explore the dark genome for rapid diagnosis and treatment of many common diseases like cancer, bipolar disorder, cardiovascular diseases, and schizophrenia.
  • Nevertheless, the Human Genome Project failed to give a complete picture of human DNA.
  • Mutations in these regions have been linked to diseases like cancer, schizophrenia, and rare diseases like age-related macular degeneration and amyotrophic lateral sclerosis (ALS).
  • As of now, NonExomics has made significant headway in research linked to the diagnosis and treatment of 22 cancers, bipolar disorder, schizophrenia, and 750 rare diseases over an eight-year period.

Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D

Retrieved on: 
Monday, June 6, 2022

Committed to delivering the most innovative NGS-based solutions, Cantata Bio comprises three business units, Epigenetics & Genome Structure, Microbial Profiling, and Genetic Analysis Solutions.

Key Points: 
  • Committed to delivering the most innovative NGS-based solutions, Cantata Bio comprises three business units, Epigenetics & Genome Structure, Microbial Profiling, and Genetic Analysis Solutions.
  • Along with the company launch, Cantata Bio announced today its Dovetail TopoLink Kit, a revolutionary new assay delivering genomic interactions at unparalleled speed.
  • Cantata Bio has seen early demand for TopoLink, having already allocated the first several kits to members of its First Adopters Circle.
  • Cantata Bio and its newest product, the Dovetail TopoLink Kit, were announced today at Advances in Genome Biology and Technology ( AGBT ), where Cantata Bio is an official sponsor.

Pyxis Oncology Announces Leadership Changes

Retrieved on: 
Wednesday, April 13, 2022

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the departure of Ronald Herbst, Ph.D., as the Company’s Chief Scientific Officer and the appointment of Jan Pinkas, Ph.D., currently Senior Vice President, Preclinical Research & Development, to the position of Chief Scientific Officer. The management changes are effective as of April 12, 2022.

Key Points: 
  • Ronalds passion, expertise and exceptional scientific leadership have been fundamental to Pyxis Oncologys growth since its founding as an IO-focused target discovery company.
  • Dr. Pinkas joined Pyxis Oncology in August 2021 as Senior Vice President, Preclinical Research & Development, responsible for leading all preclinical initiatives.
  • Prior to Pyxis Oncology, Dr. Pinkas spent ten years at Magenta Therapeutics where, most recently, he served as Senior Vice President, Translational Sciences.
  • Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improve patient lives.

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

Retrieved on: 
Wednesday, February 9, 2022

"We are pleased to share additional data from patients in Cohorts 1-3 of our RGX-121 Phase I/II trial," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.

Key Points: 
  • "We are pleased to share additional data from patients in Cohorts 1-3 of our RGX-121 Phase I/II trial," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.
  • "The data presented today continues to support the early positive signals seen in the emerging clinical profile of RGX-121 for the treatment of MPS II.
  • I am encouraged by the biomarker activity and impact on neurodevelopmental improvements observed in this trial, and I look forward to additional updates."
  • RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector.

Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology

Retrieved on: 
Wednesday, January 26, 2022

CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences , Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences , Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology.
  • We're thrilled to work with Stuart to continue that momentum, and on behalf of our team and board, we welcome Stuart to Senda and look forward to his contributions."
  • Before joining Senda, Stuart served as Vice President of Platform Biology at Korro Bio, where he built and led the high-throughput screening and platform biology functions and served on the leadership team.
  • Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines.

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

Retrieved on: 
Wednesday, January 5, 2022

Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.

Key Points: 
  • Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.
  • Dr. Vivaldi is currently the president and chief executive officer of Sigilon Therapeutics, Inc., where he also serves as a member of the company's board of directors.
  • While each rare disease impacts only a small number of people, they collectively affect an estimated 25-30 million Americans.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

DNAe, Imperial College London and the University of Leicester Collaborate on Early Detection of Recurrent Breast Cancer

Retrieved on: 
Wednesday, October 27, 2021

Together with Imperial College London (Imperial), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.

Key Points: 
  • Together with Imperial College London (Imperial), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.
  • This award formalizes a collaboration between DNAe and Professor Charles Coombes, Professor of Medical Oncology at Imperial.
  • This will enable these markers to be used to monitor treatment and detect early recurrence of breast cancer.
  • Professor Charles Coombes, Professor of Medical Oncology, Imperial, and Honorary Consultant Medical Oncologist, Imperial College Healthcare Trust, said: Cancer monitoring is a vital component of successful treatment.

Dr. David Sinclair Joins Levels as Advisor

Retrieved on: 
Tuesday, October 12, 2021

Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .

Key Points: 
  • Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .
  • Dr. Sinclair has been at the forefront of the latest discoveries in understanding why we age and how to slow its effects.
  • Dr. Sinclair joins an unprecedented group of thought leaders, clinicians, and researchers in metabolic health, and his expertise will help to drive awareness to the metabolic health crisis through content development and research in partnership with the Levels team.
  • View the full release here: https://www.businesswire.com/news/home/20211012005133/en/
    Dr. David Sinclair Joins Levels as Advisor (Photo: Business Wire)
    Im excited to work with Levels Health to empower people with the tools to optimize their bodies and help achieve longer healthspans and lifespans, says Dr. Sinclair.